Top 10 AI Stocks Dominating Wall Street

8. Lantern Pharma Inc. (NASDAQ:LTRN)

Number of Hedge Fund Holders: 3

Lantern Pharma Inc. (NASDAQ:LTRN) uses artificial intelligence, machine learning, and genomic data through its RADR platform to advance precision oncology. On January 27, the company announced improvements to its RADR® AI platform aimed at accelerating and optimizing the development of antibody-drug conjugates (ADCs). ADC is a process of creating Antibody-Drug Conjugates, a type of targeted cancer therapy for the treatment of the disease. The company’s AI-driven approach has already identified 82 promising ADC targets and 290 target-indication combinations, with some already validated for use. The AI-powered ADC module could speed up drug development by up to 50% and lower costs by 60%. It would also reduce both the time and cost of ADC development while also increasing the probability of clinical success. The company has been actively advancing multiple ADC candidates through preclinical development and has also engaged in a collaboration with the prestigious MAGICBULLET::Reloaded Initiative at the University of Bielefeld in Germany.

“The implications of this research extend far beyond just expanding the repertoire of potential ADC targets. By leveraging our RADR^® platform’s advanced AI capabilities, we’ve created a systematic approach that could dramatically reduce both the time and cost of ADC development while increasing the probability of clinical success. Our platform is particularly well-suited for partnership opportunities with pharmaceutical companies looking to accelerate their ADC programs or expand their pipeline with novel targets”.

-Kishor Bhatia, Ph.D., Chief Scientific Officer at Lantern Pharma.